Clinical Core
临床核心
基本信息
- 批准号:7646827
- 负责人:
- 金额:$ 2.47万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2009
- 资助国家:美国
- 起止时间:2009-04-01 至 2014-03-31
- 项目状态:已结题
- 来源:
- 关键词:ApoptoticArtsBiological AssayBiopsyBlood specimenBody FluidsClinicalClinical ProtocolsClinical TrialsCollaborationsColorectal CancerCyclic GMPDendritic CellsDocumentationEnrollmentEnsureEvaluationGenerationsHumanHuman bodyImmune responseImmunohistochemistryImmunologic MonitoringImmunologicsImmunotherapyInstructionLaboratoriesLaboratory StudyLinkMalignant NeoplasmsMeasuresMonitorOperative Surgical ProceduresPatient MonitoringPatientsPreparationProcessProductionRecording of previous eventsResearchResearch PersonnelRoleSamplingServicesSpecific qualifier valueSpecimenSpecimen HandlingSterilityT-LymphocyteTherapeutic InterventionTimeTissue BankingTissue BanksTissue HarvestingTissue ProcurementsTissuesTriageTumor Cell LineUniversity of Pittsburgh Cancer InstituteVaccine ProductionVaccinesbaseenzyme linked immunospot assaymelanomaneoplastic cellperipheral bloodpreclinical studyprogramsresponsetherapy designtumor
项目摘要
Core C: Immunologic Monitoring and Cellular Products Laboratory (IMCPL)
This laboratory is a specialized facility at the University of Pittsburgh Cancer Institute (UPCI), which is
dedicated to the state-of-the-art evaluation of immune responses prior to, during and after therapeutic
interventions in patients with cancer. In addition to generating cellular products for human therapy, it also
provides services for tissue procurement and processing. In its role as Core C for this PPG, the IMCPL will
assume responsibility for supporting the immunotherapy-based clinical trials proposed by the projects. Core
C, functioning as a cGMP facility, will culture and characterize dendritic cells (aDC1) for patient therapy and
prepare vaccines by loading these aDC1 with apoptotic tumor cells (ATC) (colorectal cancer (Project 1 and
4) and melanoma (Project 1)) for therapy. Core C will be responsible for quality and sterility of the aDC1-
based vaccines. Potency of aDC1 products will be measured, using the IL-12p70 production assay. Core C
will also procure and process all body fluids and tissues harvested in the course of the clinical trials. Tumor
specimens obtained at the time of surgery or biopsy tissues will be processed for use in vaccines or will be
banked for immunohistochemistry to be performed by Core B. Core C, serving as a fully certified
immunologic monitoring facility, will monitor immune responses to the administered vaccines by performing
ELISPOT assays and tetramer analyses. Core C will also be prepared to assist the PPG investigators in
implementing assays necessary for evaluation of immunologic responses to vaccines. The Core will ensure
that all cellular products it generates and samples it collects are accompanied by appropriate documentation
that will permit linking laboratory analyses with clinical results. Core C will also provide assistance in
preparation of IND submissions. The Core laboratory has a long history of collaboration with all of the
investigators, and in the context of the proposed clinical and pre-clinical studies will be entirely dedicated to
the support of this PPG.
RELEVANCE (See instructions):
核心C:免疫监测和细胞产品实验室(IMCPL)
该实验室是匹兹堡大学癌症研究所(UPCI)的专门设施,
致力于治疗前、治疗中和治疗后免疫反应的最新评估
癌症患者的干预措施。除了产生用于人类治疗的细胞产品外,它还
提供纸巾采购和加工服务。作为该PPG的核心C,IMCPL将
负责支持项目提出的以免疫疗法为基础的临床试验。堆芯
C,作为cGMP设施,将培养和鉴定树突状细胞(ADc1),用于患者治疗和
通过将凋亡的肿瘤细胞(ATC)装载到这些aDC1来制备疫苗(结直肠癌(项目1和
4)和黑色素瘤(项目1))用于治疗。核心C将负责ADC1的质量和无菌-
基础疫苗。将使用IL-12p70产生试验来测量aDC1产物的效力。核心C
还将采购和处理在临床试验过程中收集的所有体液和组织。肿瘤
手术时获得的样本或活检组织将被加工用于疫苗或将被
准备由Core B执行免疫组织化学。Core C,作为完全认证的
免疫监测设施,将通过执行以下操作来监测对接种疫苗的免疫反应
ELISPOT分析和四聚体分析。核心C还将准备协助PPG调查人员
实施评估疫苗免疫应答所需的化验。核心将确保
它产生的所有蜂窝产品和收集的样本都附有适当的文件
这将允许将实验室分析与临床结果联系起来。核心C还将在以下方面提供援助
准备IND提交的文件。核心实验室与所有
研究人员,并在拟议的临床和临床前研究的背景下,将完全致力于
这位PPG的支持。
相关性(请参阅说明):
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Theresa L. Whiteside其他文献
Tumor-infiltrating lymphocytes: their phenotype, functions and clinical use
- DOI:
10.1007/bf01517175 - 发表时间:
1994-01-01 - 期刊:
- 影响因子:5.100
- 作者:
Theresa L. Whiteside;Giorgio Parmiani - 通讯作者:
Giorgio Parmiani
Polyfunctionality of CD4+ T lymphocytes is increased after chemoradiotherapy of head and neck squamous cell carcinoma
头颈鳞状细胞癌放化疗后CD4+T淋巴细胞多功能性增加
- DOI:
- 发表时间:
2018 - 期刊:
- 影响因子:0
- 作者:
Johannes Doescher;S. Jeske;Stephanie E Weissinger;Cornelia Brunner;Simon Laban;Edwin Bölke;Thomas K. Hoffmann;Theresa L. Whiteside;P. J. Schuler - 通讯作者:
P. J. Schuler
Expression of vesiculation-related genes is associated with a tumor-promoting microenvironment: a pan-cancer analysis
- DOI:
10.1007/s12094-024-03796-8 - 发表时间:
2025-01-08 - 期刊:
- 影响因子:2.500
- 作者:
Luisa Westermann;Brenda Diergaarde;Simon Heidegger;Hendrik Poeck;Mirosław J. Szczepański;Torsten E. Reichert;Silvia Spoerl;Theresa L. Whiteside;Steffen Spoerl;Nils Ludwig - 通讯作者:
Nils Ludwig
Methods for generation of genetically modified fibroblasts for immunotherapy of cancer.
用于癌症免疫治疗的转基因成纤维细胞的产生方法。
- DOI:
- 发表时间:
1997 - 期刊:
- 影响因子:0
- 作者:
Elaine M. Elder;M. T. Lotze;Theresa L. Whiteside - 通讯作者:
Theresa L. Whiteside
Validation of plasma-derived small extracellular vesicles as cancer biomarkers
血浆来源的小细胞外囊泡作为癌症生物标志物的验证
- DOI:
10.1038/s41571-020-00433-5 - 发表时间:
2020-09-17 - 期刊:
- 影响因子:82.200
- 作者:
Theresa L. Whiteside - 通讯作者:
Theresa L. Whiteside
Theresa L. Whiteside的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Theresa L. Whiteside', 18)}}的其他基金
Core 1: Biospecimen and Translational Pathology Core
核心 1:生物样本和转化病理学核心
- 批准号:
10683754 - 财政年份:2021
- 资助金额:
$ 2.47万 - 项目类别:
Core 1: Biospecimen and Translational Pathology Core
核心 1:生物样本和转化病理学核心
- 批准号:
10469633 - 财政年份:2021
- 资助金额:
$ 2.47万 - 项目类别:
Depleting exosomes to improve responses to immune therapy in HNSCC
消耗外泌体以改善 HNSCC 免疫治疗的反应
- 批准号:
10431855 - 财政年份:2020
- 资助金额:
$ 2.47万 - 项目类别:
Depleting exosomes to improve responses to immune therapy in HNSCC
消耗外泌体以改善 HNSCC 免疫治疗的反应
- 批准号:
10640915 - 财政年份:2020
- 资助金额:
$ 2.47万 - 项目类别:
Restoring anti-tumor immunity in the microenvironment of head and neck cancer
恢复头颈癌微环境中的抗肿瘤免疫力
- 批准号:
8661142 - 财政年份:2013
- 资助金额:
$ 2.47万 - 项目类别:
Restoring anti-tumor immunity in the microenvironment of head and neck cancer
恢复头颈癌微环境中的抗肿瘤免疫力
- 批准号:
9248595 - 财政年份:2013
- 资助金额:
$ 2.47万 - 项目类别:
Restoring anti-tumor immunity in the microenvironment of head and neck cancer
恢复头颈癌微环境中的抗肿瘤免疫力
- 批准号:
8502828 - 财政年份:2013
- 资助金额:
$ 2.47万 - 项目类别:
Restoring anti-tumor immunity in the microenvironment of head and neck cancer
恢复头颈癌微环境中的抗肿瘤免疫力
- 批准号:
8828600 - 财政年份:2013
- 资助金额:
$ 2.47万 - 项目类别:
Restoring anti-tumor immunity in the microenvironment of head and neck cancer
恢复头颈癌微环境中的抗肿瘤免疫力
- 批准号:
9256442 - 财政年份:2013
- 资助金额:
$ 2.47万 - 项目类别:
相似国自然基金
Handbook of the Mathematics of the Arts and Sciences的中文翻译
- 批准号:12226504
- 批准年份:2022
- 资助金额:20.0 万元
- 项目类别:数学天元基金项目
ARTS在邻苯二甲酸(2-乙基己基)酯诱导的小鼠睾丸间质细胞凋亡中的作用及机理研究
- 批准号:
- 批准年份:2020
- 资助金额:35 万元
- 项目类别:
促进肿瘤凋亡的融合蛋白CPP-TRAIL-ARTS C27的制备及机制研究
- 批准号:81372444
- 批准年份:2013
- 资助金额:70.0 万元
- 项目类别:面上项目
雄性锹甲的生殖对策抉择ARTs及其进化机制-基于行为与SSRs标记的整合研究
- 批准号:31201745
- 批准年份:2012
- 资助金额:25.0 万元
- 项目类别:青年科学基金项目
相似海外基金
ARTS: Broadening capacity for research on gall wasps in North America
ARTS:扩大北美瘿蜂研究能力
- 批准号:
2338008 - 财政年份:2024
- 资助金额:
$ 2.47万 - 项目类别:
Continuing Grant
REU Site: Summer Research Program for Community College and Liberal Arts College Students in Physics and Astronomy
REU 网站:社区学院和文理学院学生物理和天文学夏季研究计划
- 批准号:
2349111 - 财政年份:2024
- 资助金额:
$ 2.47万 - 项目类别:
Continuing Grant
Open Access Block Award 2024 - University of the Arts London
2024 年开放获取区块奖 - 伦敦艺术大学
- 批准号:
EP/Z532216/1 - 财政年份:2024
- 资助金额:
$ 2.47万 - 项目类别:
Research Grant
Games, Heritage, Arts, & Sport: the economic, social, and cultural value of the European videogame ecosystem (GAMEHEARTS)
游戏、遗产、艺术、
- 批准号:
10104584 - 财政年份:2024
- 资助金额:
$ 2.47万 - 项目类别:
EU-Funded
Art and Policy in the Global Contemporary: Examining the Role of the Arts in the Production of Public Policy
全球当代的艺术与政策:审视艺术在公共政策制定中的作用
- 批准号:
EP/Y036972/1 - 财政年份:2024
- 资助金额:
$ 2.47万 - 项目类别:
Research Grant
Enhancing Faculty Well-being at Liberal Arts Colleges: Individual, Contextual, Institutional, and Cultural Factors
提高文理学院教师的福祉:个人、背景、制度和文化因素
- 批准号:
24K06445 - 财政年份:2024
- 资助金额:
$ 2.47万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Building Partnerships to Recruit Recent STEM Graduates into a Masters of Arts in Teaching Program
建立合作伙伴关系,招募应届 STEM 毕业生加入教学硕士项目
- 批准号:
2345165 - 财政年份:2024
- 资助金额:
$ 2.47万 - 项目类别:
Standard Grant
地理総合における対話型鑑賞法を援用したArts-STEM型教科融合授業モデルの開発
利用综合地理学中的互动欣赏方法开发艺术-STEM型学科融合课堂模型
- 批准号:
24H02463 - 财政年份:2024
- 资助金额:
$ 2.47万 - 项目类别:
Grant-in-Aid for Encouragement of Scientists
Arts4Us - Working Together to Scale up Place-Based Arts Initiatives that Support the Mental Health of Children and Young People
Arts4Us - 共同努力扩大支持儿童和青少年心理健康的地方艺术举措
- 批准号:
AH/Z505493/1 - 财政年份:2024
- 资助金额:
$ 2.47万 - 项目类别:
Research Grant
ARTS: A corevision of the pinhole borers (Coleoptera: Curculionidae: Platypodinae) and symbiotic fungi (Raffaelea spp.) via multi-generational systematics training
艺术:通过多代系统学训练对针孔蛀虫(鞘翅目:象甲科:扁豆亚科)和共生真菌(拉斐菌属)进行共同观察
- 批准号:
2342481 - 财政年份:2024
- 资助金额:
$ 2.47万 - 项目类别:
Continuing Grant